Anxamic Injection
Therapeutic Class
Antifibrinolytic
Indications
Prevention and treatment of haemorrhages due to general or local fibrinolysis in adults and children from one year. Haemorrhage caused by general or local fibrinolysis such as : Menorrhagia and metrorrhagia, Gastrointestinal bleeding, Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract, Ear Nose Throat surgery, Gynaecological surgery or disorders of obsteric origin, Thoracic and abdominal surgery and other major surgical intervention such as cardiovascular surgery, and Management of haemorrhage due to administration of a fibrinolytic agent.
Chemical Composition
Each ml contains tranexamic acid BP 100 mg
Packaging
5 x 5 ml ampoules
Dosage & Administration
Unless otherwise prescribed, the following doses are recommended : (1) Standard treatment of local fibrinolysis : 0.5g (1 ampoule of 5 ml) to 1 g (1 ampoule of 10 ml or 2 ampoules of 5 ml) tranexamic acid by slow intravenous injection (=1ml/minute) two to three times daily. (2) Standard treatment of general fibrinolysis : 1 g (1 ampoule of 10 ml or 2 ampoules of 5 ml) tranexamic acid by slow intravenous injection (=1ml/minute) every 6 to 8 hours, equivalent to 15mg/kg BW.
Contraindications
Hypersensitivity to the active substance, acute venous or arterial thrombosis, fibrinolytic conditions following consumption coagulopathy except in those with predominant activation of the fibrinolytic system with acute severe bleeding, severe renal impairment, history of convulsion, intrathecal and intraventricular injection, intracerebral application.
Side Effects
Most common side effects are gastrointestinal disorders such as diarrhoea, nausea and vomiting.
Drug Interaction
No interaction studies have been performed. Simultaneous treatment with anticoagulants must take place under the strict supervision of a physician experienced in this field. Medicinal products that act on haemostasis should be given with caution to patients treated with tranexamic acid. There is a theoretical risk of increased thrombus - formation potential such as with oestrogens. Alternatively, the fibrinolytic action of the drug may be antagonised with thrombolytic drugs.